Absci Corporation Common Stock (ABSI) Stock Price
ABSIStock
$8.25+69.40%52W
Market Cap$1.42B
P/E—
PEG Ratio—
Div yield—
Beta2.19
ABSI Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)152.00%
Price vs S&P 500 (4W)-14.66%
VGM Score27.94
ABSI Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.20 | -$0.21 | -6.38%(-$0.01) | |
| Q1 2026 | -$0.20 | -$0.19 | +4.59%(+$0.01) | |
| Q4 2025 | -$0.17 | -$0.23 | -32.54%(-$0.06) | |
| Q3 2025 | -$0.21 | -$0.20 | +2.52%(+$0.01) | |
| Q2 2025 | -$0.21 | -$0.24 | -15.07%(-$0.03) |
ABSI Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.13
4.18
4.13
4.13
Industry Peers — R&D — Physical Sciences(17)
| Symbol | Value Score | Growth Score | Momentum Score | P/E Ratio (Annual) | ROE (TTM) | Revenue Growth (5Y) | Indicated Dividend Yield (Annual) | Price |
|---|---|---|---|---|---|---|---|---|
ABSIAbsci Corporation Common Stock | F | F | B | — | -59.2% | -10.1% | — | $8.25 |
| IQVIQVIA Holdings Inc. | D | C | A | 32.3x | 21.9% | 7.5% | — | $266.90 |
| INCYIncyte Genomics Inc | C | B | B | 17.8x | 29.6% | 14.0% | — | $113.07 |
| MEDPMedpace Holdings, Inc. Common Stock | F | B | B | 38.3x | 110.2% | 22.3% | — | $618.47 |
| CRLCharles River Laboratories International, Inc. | F | D | A | — | -7.7% | 6.5% | — | $300.15 |
| ICLRIcon Plc | C | C | B | 57.3x | 0.8% | 24.1% | — | $170.18 |
| OABIOmniAb, Inc. Common Stock | F | B | A | — | -16.6% | -4.3% | — | $4.59 |
| NRCNRC Health Common Stock | D | D | B | 38.4x | 48.5% | 0.6% | 1.2% | $20.15 |
| MXCTMaxCyte, Inc. Common Stock | C | D | B | — | -21.0% | 4.8% | — | $1.30 |
| IBACIB Acquisition Corp. Common Stock | — | D | C | 15.9x | -3.7% | — | — | $10.86 |
| ONMDOneMedNet Corp Class A Common Stock | D | A | D | — | -6.8% | — | — | $4.51 |
About Absci Corporation Common Stock
Absci Corp is an AI-powered synthetic biology company focused on developing novel protein therapeutics. Its integrated platform unifies biologic drug discovery and cell line development, enabling faster creation of next-generation biologics.